Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 9.56
-0.16 (-1.65%)
Aug 13, 2026, 5:23 PM CET
Xbrane Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 76.45 | 152.35 | 148.1 | 238.73 | 57.62 | 10.71 | |
Revenue Growth | -66.36% | 2.87% | -37.96% | 314.33% | 438.03% | - |
Cost of Revenue | 33.02 | 62.81 | 18.23 | 203.34 | - | - |
Gross Profit | 43.43 | 89.55 | 129.87 | 35.39 | 57.62 | 10.71 |
Selling, General & Admin | 40.41 | 43.82 | 40.81 | 40.03 | 31.54 | 31.4 |
Research & Development | 63.95 | 117.87 | 162.01 | 305.78 | 199.65 | 160.62 |
Other Operating Expenses | 5.49 | -43.89 | 24.28 | -13.71 | -20.91 | -4.85 |
Total Operating Expenses | 109.85 | 117.8 | 227.1 | 332.11 | 210.27 | 187.17 |
Operating Income | -66.42 | -28.25 | -97.22 | -296.72 | -152.65 | -176.46 |
Interest Income | - | 0.71 | 0.5 | 2.41 | - | - |
Interest Expense | - | -16.4 | -33 | - | -2.3 | -2.64 |
Other Non-Operating Income (Expense) | -9.46 | - | - | -2.27 | - | - |
Total Non-Operating Income (Expense) | -9.46 | -15.69 | -32.5 | 0.14 | -2.3 | -2.64 |
Pretax Income | -75.88 | -43.93 | -129.72 | -322.03 | -168.51 | -183.23 |
Provision for Income Taxes | 2.32 | 2.23 | 11.59 | - | - | - |
Net Income | -78.2 | -46.17 | -141.31 | -322.03 | -168.51 | -183.23 |
Earnings From Discontinued Operations | 184.21 | 173.41 | -124.91 | -66.14 | -4 | -5.15 |
Net Income to Common | 106.01 | 127.24 | -266.22 | -388.17 | -172.51 | -188.38 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,149 | 16 | 16 | 5 | 0 | 0 |
Shares Outstanding (Diluted) | 1,149 | 16 | 16 | 5 | 0 | 0 |
Shares Change | -0.12% | - | 246.95% | 2215.66% | 8.38% | 30.25% |
EPS (Basic) | -0.60 | 0.08 | -0.22 | -82.50 | -843.75 | -997.50 |
EPS (Diluted) | -0.60 | 0.08 | -0.22 | -82.50 | -843.75 | -997.50 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -190.55 | -250.69 | -134.23 | -413.47 | -205.53 | -247.29 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.17 | -15.25 | -8.17 | -87.29 | -1004.76 | -1310.16 |
Gross Margin | 56.81% | 58.77% | 87.69% | 14.82% | 100.00% | 100.00% |
Operating Margin | -86.87% | -18.54% | -65.65% | -124.29% | -264.94% | -1647.74% |
Profit Margin | -102.29% | -30.30% | -95.42% | -134.89% | -292.47% | -1710.95% |
FCF Margin | -249.23% | -164.55% | -90.64% | -173.20% | -356.72% | -2309.16% |
EBITDA | -66.42 | -7.11 | -61.27 | -296.72 | -152.65 | -176.46 |
EBITDA Margin | -86.87% | -4.66% | -41.37% | -124.29% | -264.94% | -1647.74% |
EBIT | -66.42 | -28.25 | -97.22 | -296.72 | -152.65 | -176.46 |
EBIT Margin | -86.87% | -18.54% | -65.65% | -124.29% | -264.94% | -1647.74% |
Effective Tax Rate | -3.06% | -5.09% | -8.93% | 0.00% | 0.00% | 0.00% |